Corticosteroid Therapy for Diabetic Retinopathy

Elad Moisseiev*, Anat Loewenstein

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Inflammatory pathways as well as angiogenic factors play a role in the pathogenesis of diabetic retinopathy. Thus research has been directed to evaluate the role of corticosteroids to treat diabetic retinopathy. The mechanism of action of corticosteroids and the potential complications are reviewed. Various routes of administration have been evaluated, including intravitreal, sub-Tenon, suprachoroidal, and topical therapy. Sustained-release corticosteroid devices have been formulated to extend their therapeutic effect and potentially reduce complications. Diabetic macular edema is the most common manifestation of diabetic retinopathy that is treated with corticosteroids. Data from prospective, multicenter randomized controlled studies are presented in detail. The chapter also reviews and discusses the effect of corticosteroid therapy on diabetic retinopathy progression, as well as used in combination therapy with anti-vascular endothelial growth factor agents.

Original languageEnglish
Title of host publicationCurrent Management of Diabetic Retinopathy
Number of pages10
ISBN (Electronic)9780323549493
ISBN (Print)9780323484527
StatePublished - 2018


  • Corticosteroid
  • Cytokines
  • Diabetic macular edema
  • Flucinoloneacetonide
  • Inflammation
  • Ozurdex
  • Retisert
  • Triamcinolone acetonide


Dive into the research topics of 'Corticosteroid Therapy for Diabetic Retinopathy'. Together they form a unique fingerprint.

Cite this